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WHAT THIS PAPER ADDS
 Most patients with extensive proximal (iliofemoral) deep venous thrombosis (DVT) continue to be treated with anticoagulation
alone, despite a growing body of evidence demonstrating improved outcomes with a strategy of thrombus elimination. This study
contributes to the existing literature by focussing on the reduced likelihood of DVT recurrence as a consequence of eliminating
thrombus from the deep veins of the lower extremity.a r t i c l e i n f o
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Objectives: Iliofemoral deep venous thrombosis (IFDVT) is an independent risk factor for recurrent DVT. It
has been observed that recurrent DVT correlates with residual thrombus. This study evaluates whether
risk of recurrence is related to the amount of residual thrombus following catheter-directed thrombolysis
(CDT) for IFDVT.
Methods: Patients who underwent CDT for IFDVT had their degree of lysis quantiﬁed by a reader blind to
the patients’ long-term clinical outcome. Patients were classiﬁed into two groups, 50% and <50%
residual thrombus. Recurrence was deﬁned as a symptomatic presentation with image veriﬁcation of
new or additional thrombus.
Results: A total of 75 patients underwent CDT for IFDVT. Median follow-up was 35.9 months. Sixty-eight
patients (91%) had no evidence of recurrence and seven (9%) developed recurrence. Of the patients who
had 50% (mean 80%) residual thrombus, 50% (4/8) experienced recurrence, but in those with <50%
(mean 35%) residual thrombus, only 5% (3/67) had recurrent DVT (P ¼ 0.0014).
Conclusion: The burden of residual thrombus at completion of CDT correlates with the risk of DVT
recurrence. Patients having CDT for IFDVT had a lower risk of recurrence than expected. Successful
clearing of acute clot in IFDVT patients signiﬁcantly reduces the recurrence risk compared to patients
with a large residual thrombus burden.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The iliofemoral segment of the venous system is the single
outﬂow channel for the lower extremity. Occlusion of this outﬂow
tract leads to high venous and compartment pressures acutely,1
and increased venous pressures and post-thrombotic morbidity
as long-term sequelae.2 The post-thrombotic syndrome (PTS),ebruary 2011 (Winner, 2011
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ciety for Vascular Surgery. Publisha debilitating condition that reduces health-related quality of life,3
occurs more frequently in patients following ipsilateral recurrent
deep venous thrombosis (DVT). Iliofemoral DVT (IFDVT) is associ-
ated with a higher risk of recurrence than infrainguinal DVT,
reaching 12% at 3 months.4 Each episode of recurrence increases
the severity of the PTS.5 In addition to its more proximal location,
a signiﬁcantly greater thrombus burden differentiates IFDVT from
infrainguinal DVT.
Strategies of thrombus removal have been selectively offered to
patients with extensive DVT in an attempt to reduce post-
thrombotic morbidity. Venous thrombectomy has shown better
results than anticoagulation alone for patients with IFDVT,6e8 buted by Elsevier Ltd. All rights reserved.
Figure 1. KaplaneMeier curve illustrates correlation between percent of residual
thrombus and recurrence of DVT in a 3-year period.
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thrombolytic therapy performed with current techniques has
been associated with success in 70e90% of cases with reduced risk
of bleeding.9e12 Successful catheter-directed thrombolysis (CDT)
for IFDVT has been associated with a reduction in thrombus burden
and PTS and, as a result, improved quality of life.13 Baekgaard et al.12
reported a lower than expected recurrence rate 6 years following
CDT for acute IFDVT. One might expect that patients with lesser
amounts of thrombus after catheter-based thrombolysis will have
a lower risk of recurrent DVT.
The purpose of this study is to determine the rate of recurrent
DVT in patients with IFDVT treated by catheter-based techniques of
thrombus removal and to assess whether recurrence correlates
with the amount of residual thrombus at the completion of CDT.
Methods
Consecutive patients with symptomatic acute DVT involving the
iliofemoral or vena caval segments (with or without infrainguinal
DVT) who were treated with CDT form the basis of this study. This
study was approved by the institutional review board.
Access for CDT was obtained with ultrasound guidance into the
ipsilateral popliteal vein, common femoral vein and/or posterior
tibial vein, depending upon the location and extent of thrombosis.
Vena caval imaging was performed in all patients to assess
whether thrombus extended into or involved the vena cava. Vena
caval ﬁlters were placed in approximately 30% of patients prior to
CDT. They were uniformly used in patients with free-ﬂoating
thrombus in the inferior vena cava and at the discretion of the
interventionalist.
The details of the technique of CDT have been previously
reported.14 Brieﬂy, patients were treated with recombinant tissue
plasminogen activator (rt-PA) at a dose of 1e1.5 mg h1 depending
on thrombus volume and number of catheters used. The concen-
tration of rt-PA varied from 1 mg/50 cc to 1 mg/100 cc NaCl.
Pharmacomechanical thrombolysis was integrated into patient care
as these techniques became available. These procedures used
rheolytic, isolated segmental and/or ultrasound-accelerated lytic
catheters.
Rheolytic thrombectomy was used for segmental thrombus.
Isolated, segmental pharmacomechanical thrombolysis became the
preferred initial approach to reduce thrombus burden. This tech-
nique uses the double-balloon Trellis catheter (Covidien, Mans-
ﬁeld, MA, USA) to segmentally dissolve andmacerate the thrombus.
Residual thrombus was treated with the standard drip technique.
Following lysis, balloon catheters were used as needed to dilate
areas of stenosis, except in the case of an iliac vein stenosis, where
balloon venoplasty and stenting were performed to ensure unob-
structed venous drainage from the common femoral vein into the
vena cava.
CDT was terminated when maximal beneﬁt from the procedure
was obtained, as determined by the treating physician, increased
concern for bleeding, clinical bleeding or patient request. CDT using
the drip technique alone often continued 48e72 h and occasionally
longer. Since the integration of pharmacomechanical techniques,
no treatment time has exceeded 24 h.
Intravascular ultrasound was not used in the management of
these patients. Serial ultrasound examinations were not performed
during the course of treatment; however, they were performed
uponpatient presentation, prior to discharge, and during follow-up.
Following CDT, all patients were therapeutically anticoagulated
with intravenous unfractionated heparin (UFH) or subcutaneous
enoxaparin and converted to oral anticoagulation with warfarin.
The duration of anticoagulation was generally longer than that
recommended by existing guidelines,15 with nearly all patientstreated for 1 year and many longer if bleeding risk was low and the
patient was compliant.
The degree of clot lysis was retrospectively evaluated by review of
the phlebograms performed before and after treatment using
a modiﬁcation of the venous scoring method described by Mewissen
et al.9 and previously reported by Martinez et al.16 Nine venous
segments (inferior vena cava, common iliac, external iliac, common
femoral, proximal femoral, distal femoral, popliteal, tibial andprofunda
femoris veins) were analysed and scored as follows: 0, thrombus-free
(normal) segment; 1, 1e49% luminal reduction by thrombus and/or
stenosis; 2, 50e99% luminal reduction; and 3, occluded. The percent
of clot lysed was calculated by subtracting the post-treatment
thrombus score from the pretreatment thrombus score and dividing
by the pretreatment score. The physician interpreting the phlebo-
grams was blinded to the clinical outcomes of the patients, and the
physicianperforming the clinical evaluation and treating the patient’s
recurrence was not aware of the patient’s phlebographic score.
Patients were grouped by quantity of residual thrombus: 50%
residual thrombus versus <50% residual thrombus. All were fol-
lowed up with serial clinical examinations and venous duplex
ultrasounds. Recurrence was deﬁned by patients presenting with
symptoms of recurrent pain and/or swelling, the presence of a new
noncompressible vein segment previously free of thrombus on
duplex ultrasound, extension of a previous ﬁlling defect into
a previously uninvolved segment or a new intraluminal ﬁlling
defect that was viewed in two or more projections on venogram.
Due to the small number of cases in this study, we used the
nonparametric log-rank test rather than the asymptotic chi-
squared test to compute the P-values.
Results
Seventy-ﬁve patients underwent CDT for IFDVT. The mean age
of the patients was 48 years and 32 (43%) were female and 43 (57%)
male. Mean duration of follow-up was 35 months and the median
was 35.9; the interquartile (IQR) range was 44 months. Patients
who had pharmacomechanical thrombolysis had better lytic
outcomes than those having the drip technique alone. These data
were addressed in a previous publication.16
Seven (9%) patients developed recurrent DVT, six within 3 years
and one at 6.5 years. The 3-year recurrence rate was 8% (6/75).16
Eight patients had 50% residual thrombus (mean 80%) and 67
patients had <50% (mean 35%). The recurrence rate at 3 years
among the group of patients with50% residual thrombus was 38%
(3/8), and the overall recurrence rate was 50% (4/8). One patient
developed recurrent DVT 6.5 years after the initial event. The
recurrence rate at 3 years and overall recurrence for those with
<50% residual thrombus was 5% (3/67; P ¼ 0.0014) (Fig. 1).
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This study shows that patients with IFDVT treated with CDT
have fewer recurrences when compared to previous reports of
IFDVT patients treated with anticoagulation alone4 and that
patients with a greater volume of residual thrombus when CDTwas
completed were at a higher risk for recurrence. Prior studies have
shown a correlation of thrombus volumewith recurrence. Douketis
et al.4 followed 1149 patients with acute DVT treated with anti-
coagulation alone and reported that patients with IFDVT had a 12%
3-month rate of recurrence, a rate 2.4 patients with infrainguinal
DVT. The authors concluded that IFDVT was an independent
predictor of recurrence.
The observations reported in this study show that a catheter-
based strategy of thrombus removal reduces the high rate of
recurrence and suggests that the quantity of residual thrombus at
completion of CDT directly correlates with recurrent episodes of
DVT. When a high degree of clot lysis is achieved, patients have
fewer recurrences.
Further support for these observations was provided by Pran-
doni and colleagues17 when they performed a prospective study of
313 patients with proximal DVT who were treated with anti-
coagulation alone. Their patients represented the spectrum of
acute DVT, not just IFDVT. When venous duplex ultrasounds were
reviewed after the discontinuation of anticoagulation, 70% of
patients with obstruction on venous duplex had a recurrence rate
compared to 29% of patients with no evidence of residual thrombus.
The authors found that residual luminal obstruction was an inde-
pendent predictor of recurrence (HR 2.4, 95% CI:1.3e4.4; P¼ 0.004).
The REVERSE investigators,18 who followed up patients with
acute DVT treated with anticoagulation alone, failed to conﬁrm
a statistical association of residual luminal abnormalities on ultra-
sound at the time anticoagulation was discontinued with recur-
rence. They found a 40% increased risk of recurrence with a positive
compression ultrasound; although not reaching signiﬁcance, the
point estimate supports the concept.
Tan et al.19 performed a systematic review and concluded that
residual venous thrombosis was a signiﬁcant predictive factor for
recurrence. Similar ﬁndings were observed in a prospective study
by Piovella et al.20 in which the authors monitored 283 patients
with proximal DVT with serial duplex ultrasounds over a 12-month
period. All patients were treated with anticoagulation alone.
Within 1 year, 7.1% of patients had recurrent DVT. Eighty percent of
patients with DVT recurrence had residual thrombus. The odds
ratio for recurrent DVT due to residual thrombus in cancer-free
patients was 11.29 at 3 years (P ¼ 0.002).
There is a difference between residual thrombus following CDT
and ﬁndings on compression ultrasound many months later at
a time when anticoagulation is terminated. The phlebographic
images showing luminal defects at the completion of CDT more
likely represent thrombus, while the ﬁndings on the ultrasound
images months or years later represent intraluminal ﬁbrosis.
Although not equivalent structurally, residual thrombus leads to
intraluminal ﬁbrosis, and it is reasonable to conclude that the larger
the burden of residual thrombus following CDT, the greater the
subsequent intraluminal ﬁbrosis.
From a pathophysiologic standpoint, the characteristic dis-
tinguishing IFDVT from DVT in other locations is the volume of
thrombus. Therefore, thrombus burden in patients with IFDVT may
provide a clinically relevant predictor for recurrent DVT. A growing
body of evidence suggests the importance of thrombus burden in
determining the long-term sequelae of IFDVT.12,14,21,22
Breddin et al.23 conducted a multicentre randomised controlled
trial comparing the efﬁcacy of low-molecular-weight heparin
(Raviparin) to unfractionated heparin in 1148 patients with acuteDVT. Patients were diagnosed with an initial phlebogram and
underwent a repeat phlebogram 3 weeks later. One of the
secondary end points was recurrent venous thrombo-embolism
(VTE). The authors found a statistical correlation (P ¼ 0.0011)
between the amount of residual venous thrombus on phlebography
and subsequent recurrence.
Hull et al.24 performed a meta-analysis of studies correlating the
quantity of residual thrombus to subsequent recurrence. The
results favoured a correlation between degree of clot burden and
recurrent VTE episodes (RR 0.56, 95% CI 0.42e0.56; P < 0.001). The
aggregate analysis showed a striking predictive correlation for
thrombus burden change and subsequent recurrent VTE episodes
(P ¼ 0.005).
Patients with symptomatic IFDVT represent a subset of lower
extremity DVT patients with large thrombus burdens. It makes
intuitive sense that reduction in the amount of clot should reduce
recurrence. Our study shows that not all patients treated with CDT
for IFDVT have elimination of their clot and that those with high
degrees of residual vein thrombus were more prone to recurrence.
Incorporating pharmacomechanical methods during CDT
improves outcomes, shortens treatment time and uses lower doses
of rt-PA. Martinez et al.16 reported signiﬁcantly better treatment
results, a 58% reduction in treatment times, and a 44% reduction is
dose or rt-PA.
Thrombophilia evaluations were not performed in all patients.
Initially, thrombophilia testing was performed if it could be done
reliably. Since non-DNA thrombophilia testing is inaccurate during
the acute phase of thrombosis and during anticoagulation, testing
was delayed early in our experience. As large cohorts of thrombo-
philia patients were followed up, it has been observed that
thrombophilia testing has little, if any, value in the management of
these patients.25 Therefore, thrombophilia evaluations were not
requested in the late part of this study.
A limitation of this study is that it is retrospective with no
control patients treated with anticoagulation alone. A number of
our patients were referred after failed initial treatment with anti-
coagulation alone, or failed attempts at CDT. Therefore, the
outcomes observed here may not represent those expected in
a nonreferral practice.
The strengths of this study are that all patients with iliofemoral
DVT who were treated with CDT are included in this analysis. All
had pre- and post-treatment phlebography. Phlebographic evalu-
ations were performed by physicians who were blinded to the
clinical outcomes of patients, and physicians caring for patients
were unaware of the details of lytic outcome.
This is the ﬁrst report suggesting a direct relationship between
the phlebographic degree of residual thrombus with recurrent DVT
following CDT. It is our impression that there is a more linear
correlation of recurrence with residual thrombus than reported
here; however, much larger patient numbers will be required to
demonstrate such a linear relationship. We found no correlates
with recurrent thrombosis other than residual thrombus. More-
over, the diagnosis of recurrent DVT was made by physicians who
were unaware of the success of CDT for patient’s initial IFDVT. We
are optimistic that as more information is gathered on the beneﬁts
of strategies of thrombus removal for patients with IFDVT, treat-
ment designed to eliminate thrombus, restore patency and
preserve valve functionwill bewidely adapted. This should result in
fewer recurrences, less post-thrombotic morbidit, and improved
health-related quality of life.
An NIH-funded trial, ATTRACT (Acute Venous Thrombosis:
Thrombus Removal with Adjunctive Catheter-directed Thrombol-
ysis), is currently in progress, which is randomising patients with
proximal DVT to anticoagulation alone or to CDT and anti-
coagulation.26 Patients will be stratiﬁed at randomisation with
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DVT. ATTRACT will help answer the questions of whether CDT
improves outcomes after DVT, reduces PTS, reduces recurrence and
is cost-effective. However, in the absence of deﬁnitive data from
randomised controlled trials, observational evidence suggests that
CDT restores patency, preserves valve function and improves
quality of life. Observations from this study now show that the risk
of recurrent DVT is diminished following treatment with CDT and
that risk of recurrence is related to residual thrombus.
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